All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2024-03-01.
From the record
OPKO Health, Inc.'s filings since 2017 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-03-01) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-6.6% a year over 10 filed years; profitable in 1 of 10.
From the record
OPKO Health, Inc.'s 10 filed years say what it did: revenue went from $1.1 billion in fiscal 2016 to $607 million in fiscal 2025, down 6.6% a year; it rose in 3 of 9 years; the deepest fall was 66% from fiscal 2021 to fiscal 2025; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: OPKO Health, Inc.'s shareholder treatment is put at 8.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 18% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -18%: lost 18¢ per shareholder dollar. Leverage 34%: owes 34¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, OPKO Health, Inc. lost about 18 cents for every dollar of shareholders' money, and gross profitability: its products earned about 11 cents per dollar of everything the company owns. Leverage: it owed about 34 cents per dollar of assets, and net share issuance: its share count grew 8.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 44% of 315 in its family; net margin -37.2%.
From the record
OPKO Health, Inc.'s standing among 315 graded names in its industry family: revenue of $607 million in fiscal 2025 ranks in the top 17% by size; a net margin of -37.2% ranks in the top 38%; revenue growth of -15.5% a year over the last 3 filed years ranks in the bottom 23% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 17% of 315 in its family for leadership; chief executive since 2007.
From the record
OPKO Health, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Frost, Phillip Md Et Al (CEO & Chairman, as filed), filing under that title since 2007-03-30, 19.6 years (top 3% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 19.6 years (top 1%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 35% of 273 in its family for room to expand.
From the record
OPKO Health, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $364 million against debt of $2 million leaves 18.7% of its assets as net cash, bottom 37% of its family; cash from operations less capital spending is -31.4% of revenue (top 41%); a gross margin of 33.9% (bottom 18%); research spending of 20.4% of revenue (bottom 25%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 46% of 306 in its family for growth drivers.
From the record
OPKO Health, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -15.5% a year over the last three filed years against -6.6% over all 10, slowing (bottom 37% of its family); the newest year grew -14.9% (bottom 28%); research spending grew 18.8% a year (top 26%); capital spending grew -20.6% a year (bottom 43%) (its annual reports). OPKO Health, Inc. reported 3 product lines in fiscal 2025: Service at $370 million (61%), Product at $157 million (26%), Transfer of Intellectual Property and Other at $80 million (13%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 39% of 233 in its family for expectations against reality.
From the record
OPKO Health, Inc.'s newest year against its own record: revenue of $607 million in fiscal 2025 came in 1% above the $601 million its prior three years' pace pointed to (top 43% of its family); net income of $226 million against a prior three-year average of $190 million (bottom 34%); a net margin of -37.2% against -20.7% before (bottom 27%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made